Archive: October 2025

Cancer and Cardiovascular Health: A Multidisciplinary Approach

Abstract: Early detection and improved cancer therapies have led to increases in cancer survivorship. There were 18.1 million cancer survivors in the United States alone in […]

Targeted Immunotherapy in the Treatment of Childhood and Adolescent Mature B-Cell Lymphoma

Abstract: Mature B-cell non-Hodgkin lymphomas (B-NHLs) comprise approximately 40% to 60% of all NHLs among children, adolescents, and young adults. Although overall survival with mature B-NHL […]

Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

H&O  Could you describe the ENZA-p trial that you and your colleagues conducted?  LE  ENZA-p was a randomized phase 2 trial that took place at 15 […]

Neoadjuvant Therapy in Melanoma: A New Standard of Care

H&O  How do you define neoadjuvant therapy in melanoma? NK  In true neoadjuvant therapy, a defined dose and schedule of preoperative therapy are given with the […]

Using Imetelstat for Lower-Risk Myelodysplastic Syndromes

H&O  Who is eligible for treatment with imetelstat?  VS  Imetelstat (Rytelo, Geron) is approved for use in adults with myelodysplastic syndromes (MDS) of low to intermediate-1 […]

Letter From the Editor: Patients’ Stories

I love a good book. It’s not often these days that I get to enjoy a novel, cover to cover, over a week or two. Sure, I […]

The Use of Antibody-Drug Conjugates in Gynecologic Cancers

H&O  What makes antibody-drug conjugates (ADCs) particularly promising for treating gynecologic cancers in comparison with traditional chemotherapy? JL  ADCs are a form of targeted chemotherapy. When […]

Back to Archive